---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-209899"
form_type: "8-K"
ticker: "GENB"
cik: "0002100782"
company_name: "Generate Biomedicines, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:07:53.837668+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Generate Q1 net loss widens to $61.7M, cash $516.6M post-IPO; pipeline advances

## Summary
- Net loss $61.7M vs $44.3M YoY; revenue $7.2M (down 18% from $8.8M).
- Cash & equivalents $516.6M, includes $369.3M IPO proceeds; runway into H1 2028.
- GB-0895 (anti-TSLP) Phase 3 SOLAIRIA-1/2 ongoing in severe asthma; Phase 1b in COPD.
- GB-4362 (MMAE neutralizer) FDA Fast Track; first patient dosing expected mid-2026.
- GB-5267 (MUC16 armored CAR T with Roswell Park) first patient expected H2 2026.

## SEC filing metadata
- accession: 0001193125-26-209899
- form_type: 8-K
- ticker: GENB
- cik: 0002100782
- company_name: Generate Biomedicines, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2100782/000119312526209899/0001193125-26-209899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2100782/000119312526209899/ck0002100782-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-209899
- JSON: https://secwatch.observer/filing/0001193125-26-209899.json
- Plain text: https://secwatch.observer/filing/0001193125-26-209899.txt

## Source-grounded claims
- claim_id: e254dc45f97cdcae99b8a796ae44bc9c474f4ea3
  claim: Generate Biomedicines, Inc. reported the first quarter ended March 31, 2026 results: revenue $7.2 million, net income Net loss was $61.7 million.
  evidence_excerpt: its operations into the first half of 2028. Generate expects to require additional capital to support long-term operations. Revenue for the quarter ended March 31, 2026, was $7.2 million, compared with $8.8 million for the same period in 2025. This revenue reflects developments in the ongoing Amgen and Novartis research programs. Research and development expenses
  evidence_url: https://www.sec.gov/Archives/edgar/data/2100782/000119312526209899/0001193125-26-209899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.